The Tumor-Immune Microenvironment and Response to Radiation Therapy by Stephen L. Shiao & Lisa M. Coussens
The Tumor-Immune Microenvironment and Response
to Radiation Therapy
Stephen L. Shiao & Lisa M. Coussens
Received: 22 November 2010 /Accepted: 3 December 2010 /Published online: 16 December 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Chemotherapy and radiation therapy (RT) are
standard therapeutic modalities for patients with cancer,
including breast cancer. Historic studies examining tissue
and cellular responses to RT have predominantly focused on
damage caused to proliferating malignant cells leading to their
death. However, there is increasing evidence that RT also
leads to significant alterations in the tumor microenvironment,
particularly with respect to effects on immune cells infiltrating
tumors. This review focuses on tumor-associated immune cell
responses following RTand discusses how immune responses
may be modified to enhance durability and efficacy of RT.
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Introduction
A role for leukocytes in solid tumor development has long
been suspected [1]; however, only recently have immune-
competent spontaneous models of human cancer develop-
ment enabled mechanistic evaluation of leukocytes to
determine if their presence in solid tumors is coincidental
or functional. With the advent of mouse models of multi-
stage neoplastic progression, it is now clear that lymphoid
and myeloid cells can either restrain or propel cancer
development, depending on their maturation state, as well
as the local microenvironment regulating their bioeffector
phenotype [2–4]. A role for immune cells as mediators of
therapeutic response in cancers has only recently been
explored [5, 6].
Chemotherapy (CTX) and radiation therapy (RT) remain
as part of the standard therapeutic armament for patients
with cancer, including breast cancer (BC) [7]. Both CTX
and RT impact growing cancers through their ability to
induce cell death by disrupting various parameters of cell
biology necessary for survival. However, recent data has
emerged demonstrating that the type of cell death induced
by cytotoxic therapy is significant with regards to the type
of immune response elicited within a tissue [8]. These
studies have revealed that effectiveness of CTX and RT
may in part depend on whether cell death (induced by
cytotoxic therapy) is “sensed” by leukocytes [5, 9, 10].
Leukocytes detect cell death through immune-based
receptors for molecules released by dying cells (often
termed “danger signals”), such as toll-like receptor
(TLR)-4 and its ligands including the high-mobility
group box protein (HMGB) 1 [11]. Detection of danger
signals in tissues by leukocytes activates an immune
response involving cells of the innate (myeloid and natural
killer cells) and adaptive (T and B cell) lineages. This
review will focus on immunologic consequences of RT
and discusses emerging data indicating that therapeutic
reprogramming of immune responses in tumors may
regulate efficacy and durability of RT.
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Immune Cells and Cancer Development
Cancer research has primarily focused on the role of
activating and/or inactivating mutations in genes regulating
aspects of cell proliferation or cell death. Much of that
research has been geared towards understanding how these
activating and/or inactivating mutations support the multi-
step model of tumorigenesis where progressive accumula-
tion of genetic changes in somatic cells act as drivers of
cancer development [12]. This neoplastic cell-intrinsic
perspective of multi-stage tumorigenesis overlooks progres-
sive alterations in the tumor microenvironment that also
regulate cancer development [13]. Solid tumors contain
neoplastic and non-neoplastic stromal cells embedded in a
dynamic extracellular matrix (ECM) microenvironment.
Cellular components of tumor stroma include hematog-
enous and lymphatic vascular cells, infiltrating and
resident leukocytes, various populations of fibroblasts
and mesenchymal support cells unique to each tissue
microenvironment. Clinical and experimental studies
have established that chronic infiltration of neoplastic
tissue by leukocytes, i.e., chronic inflammation, promotes
development and/or progression of solid tumors. However,
the organ-specific cellular and molecular programs that favor
pro-tumor, as opposed to anti-tumor immunity by leukocytes
remain incompletely understood.
Retrospective clinical studies have revealed an increased
presence of extra follicular B cells, T regulatory (Treg) cells,
high ratios of CD4/CD8 or TH2/TH1 T lymphocytes in
primary tumors or in draining lymph nodes that correlate
with tumor grade, stage and overall survival (OS) [14–22].
Lymphocyte density in pretreatment biopsies has also been
found to represent an independent predictor of complete
pathologic response following anthracycline and taxane-
based chemotherapy [23]. On the other hand, high densities
of macrophages in BC stroma, and some other solid tumors,
correlates with increased vascular density and worse
clinical outcome [24–29]. Infiltration of macrophages
inside tumor nests however, particularly when CD8+
cytotoxic lymphocytes (CTL) are also present, correlates
with increased overall survival (OS) [30]. These differences
might be explained in part by the realization that
macrophages exert either pro- or anti-tumor bioactivities
depending on the types of cytokines to which they are
exposed. Macrophages exposed to TH1 cytokines including
interferon (IFN)γ, tumor necrosis factor (TNF)α, and
granulocyte monocyte-colony stimulating factor (GM-CSF)
exhibit enhanced cytotoxic activity, production of pro-
inflammatory cytokines and antigen presentation [31, 32].
On the other hand, macrophages exposed to TH2 cytokines
such as interleukin (IL)-4 and -13, immune complexes or
immunosuppressive cytokines [31] instead block CTL
activity and promote angiogenesis and tissue remodeling
[33, 34]. Thus, the presence of leukocytes can exert either a
positive or negative force depending on the functional
properties they possess.
Radiation Therapy and Activation of Stress Response
Pathways
Historically, RT was thought to induce an immunosuppres-
sive microenvironment largely based on experimental
studies with whole body irradiation revealing lower levels
of circulating lymphocytes resulting from increased
radiation sensitivity of bone marrow as compared to other
tissues [35]. Fas, a cell surface proapototic protein and
member of the tumor necrosis factor receptor (TNF-R)
family, contains an intracellular "death domain" that is
activated following ligand binding that subsequently
leads to apoptosis. Fas is expressed on many cell types
including lymphocytes and is upregulated in response to
cell damage. Activation of Fas-mediated cell death is a
mechanism by which immune cells eliminate damaged
cells, including those damaged by RT [36]. Thus, while
whole body radiation is “immunosuppressive” due to
triggering widespread apoptosis of immune cells via Fas,
focal radiation such as that used for treatment of many
types of solid tumors instead has limited immunosuppres-
sive side effects, and may actually promote changes in the
local tumor microenvironment that paradoxically enhance
infiltration and activation of multiple immune cell types
(Fig. 1) that may either foster, and/or suppress tumor
development [2].
At the most simplistic level, a main mechanism by
which ionizing radiation mediates a biologic effect is via
generation of free radicals that lead to genotoxic (DNA)
damage, and subsequent activation of stress-response path-
ways through activation of the DNA damage pathway
ataxia telangiectasia mutated (ATM). Activation of the
ATM protein pathway following RT involves activation of
p53 and nuclear factor (NF)-κB transcription factors [37,
38]. NF-κB can also be activated independently of DNA
damage through radiation-induced activation of TNFR-
associated factors (TRAFs) [39, 40]. NF-κB directly
regulates expression of molecules that promote a “pro-
inflammatory” immune response, including TNF-α [41],
interleukin (IL)-1 [42], chemokines such as CCL5 [43];
adhesion molecules including intracellular adhesion mole-
cule (ICAM)-1 [44, 45], E-selectin [46] and vascular cell
adhesion molecule (VCAM)-1 [47], as well as major
histocompatability complex (MHC) molecules (Fig. 2)
[48], and expression of several anti-apoptotic genes
including Bax and Bcl-2 [49–52]. Signaling cascades
induced by radiation through ATM/NF-κB, in addition to
the direct cell death resulting from radiation damage,
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stimulates influx and activation of leukocytes leading to a
productive immune response.
Immune Responses to Radiation
RT and Cytokine Expression Cytokines are peptide-type
regulatory proteins, such as the interleukins and lympho-
kines, released by immune cells leading to generation of an
immune response. Some cytokines act to inhibit immune
responses, e.g. IL-10 and transforming growth factor
(TGF)-β, or instead stimulate immune responses, e.g.,
TNF-α or IL-1 [53]. TNF-α and IL-1 are pro-
inflammatory cytokines that also mediate leukocyte recruit-
ment in tumors [53, 54]. In the 1980’s, Hallahan and
colleagues reported that TNF-α mRNA and protein levels
were increased in human sarcoma cells following RT, an
effect that sensitized tumor cells to radiation-induced cell
Figure 1 Leukocyte infiltration following RT. Representative tissue
sections of mammary carcinomas stained with hematoxylin and eosin (A)
following isolation from a murine mammary carcinoma 96 h after
receiving 5 Gy of localized gamma irradiation. CD45+ staining (red) of
adjacent tissue sections (B) demonstrates extent of leukocyte infiltration
following RT. The percentage change in CD45+ cell infiltration was
assessed by flow cytometry of whole tumor cell suspensions revealing a
significant increase in CD45+ cells following RT.
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death [55]. Macrophage-derived IL-1α and IL-1β have also
been found increased in response to RT in vivo following
sublethal total body irradiation [56–58], as also have IL- 6
[59] and TGF-β [60]. Consequences resulting from the
release of these cytokines are recruitment and activation of
leukocytes from peripheral blood and extravasation into
tissue (tumor) parenchyma as is illustrated in Fig. 1.
Adhesion Molecules Regulated by RT Adhesion molecules
are proteins located on the cell surface that mediate
interaction with other cells or extracellular matrix. Cell
adhesion molecules such as ICAM-1, E-selectin and
VCAM-1 are upregulated on endothelial cells during
inflammation and are critical for leukocyte trafficking
across endothelial barriers [61]. Vascular endothelial cells
within tumor vessels respond to RT by upregulation of
ICAM-1 and E-selectin and thereby facilitate leukocyte
arrest and adhesion prior to transmigration [62]. Blockade
of CD11b, the ligand for ICAM-1, in a transplantable
murine squamous carcinoma model significantly reduced
tumor-infiltration by CD11b+ myeloid cells following RT
resulting in diminished tumor growth [63]. Similarly,
examination of tumor tissue removed from head and neck
cancer patients following RT revealed marked increase in
endothelial ICAM-1 expression, in concert with increased
β2 integrin-positive myeloid cell infiltration [64]. Other
adhesion molecules are also regulated by RT including
VCAM-1 in melanoma in an interferon (IFN)γ-dependent
manner [65].
Chemokines and RT Chemokines are a family of small
chemotactic cytokines that regulate directional migration of
cells expressing a cognate chemokine receptor. While some
chemokines are important for homeostatic circulation of
leukocytes, others are induced following tissue damage.
Two important chemokines regulated by RT are CXCL16
and SDF-1. Using a murine model of mammary carcino-
genesis, Matsumura and colleagues reported that CXCL16,
which is upregulated in tumors following RT, induced
recruitment and activation of T cells expressing CXCR6,
the ligand for CXCL16. Mice deficient for CXCR6
exhibited decreased CD8+ T cell recruitment in tumors
and decreased RT responsiveness [66]. Murine melanoma,
fibrosarcoma and colon carcinoma cell lines in vitro
upregulate CXCL16 in response to RT indicating that
CXCL16 expression may be a common response across
many tumor types [67]. Thus, radiation-induced CXCL16 is
an important mechanism by which RT promotes CD8+ T
cell infiltration leading to tumor suppression.
Stromal cell-derived factor (SDF)-1α is also upregulated
following RT in bone marrow-derived cells [68] and cell
lines derived from brain tumors [69]. Using an in vivo
model, Kozin and colleagues observed that lung and breast
xenograft tumors responded with increased CD11b+F4/80+
macrophage infiltration following RT that was dependent
on expression of SDF-1α. Inhibition of the SDF-1α
pathway with a small molecule inhibitor blocking the
interaction of SDF-1α and CXCR4 prevented infiltration
of macrophages and significantly delayed tumor regrowth
following RT [70]. Studies such as these indicate that RT
upregulates expression of some chemokines (CXCL16 and
SDF-1α) that can in turn regulate presence of either tumor
suppressive lymphocytes (CD8+ T cells), or tumor-
promoting cells such as macrophages.
Figure 2 Schematic of the immune response to RT. Tumor cells
respond to ionizing RT by upregulating cytokines (TNFα, IL-1α/β
and IL-6), adhesion molecules (ICAM-1, VCAM-1, E-selectin) and
MHC Class I. Death of tumor cells also generates release of
inflammatory molecules HMGB1 and ATP. This response recruits
macrophages and DCs to tumors where they then receive activation
signals resulting in their migration to draining lymph nodes where
APCs (macrophages and dendritic cells) present tumor-derived
antigens and stimulate T cell responses. Tumor-specific T cells then
re-infiltrate tumors and induce death of damaged malignant cells.
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RT and Antigen Presentation Once leukocytes have
migrated into sites of tissue damage in response to
cytokines and chemokines, functional antigen-presenting
cells (APC) are required for a productive anti-tumor T cell
response to ensue. APCs capture antigens, and following
processing, present them on their cell surface via MHC. T
cells recognize antigens bound to MHC and respond by
proliferating and generating anti-tumor T cells responses.
Lugade and colleagues, utilizing a transplantable murine
model of melanoma, reported increased expression of MHC
class I on tumor cells following RT [71], a response also
observed on GL261 glioma tumor cells [72], indicating that
RT enhances tumor cell recognition by T cells through
upregulation of MHC class I on the surface of tumor cells,
as well as on the surface of APCs [73, 74]. Increased
presence of radiation-specific peptides has also been
identified as a mechanism whereby tumor-specific T cell
responses are elicited by RT [75], a mechanism that also
contributes to enhanced anti-tumor immunity.
RT-Induced Immunogenic Cell Death Radiation of tumor
cells generally produces two responses: proliferative arrest
(which in the case of senescence is indefinite) or cell death.
Tumor cell death can occur by several mechanisms
including apoptosis, necrosis, autophagy or mitotic catas-
trophe. Apoptosis is a stereotyped pattern of morphological
changes involving chromatin condensation (pyknosis),
nuclear fragmentation (karyorhexis), shrinkage of cytoplasm,
blebbing of plasma membranes, and final disintegration of
cells into membrane-surrounded apoptotic bodies [76, 77].
While often observed in vitro, apoptosis is rarely seen in vivo
since dying cells are efficiently recognized, engulfed and
eradicated by neighboring cells before they enter the late
stages of the apoptotic process [78]. Necrosis is charac-
terized by cell swelling followed by rupture of plasma
membranes and subsequent spillage of cellular contents
into intercellular spaces. Autophagy is marked by seques-
tration of large parts of the cytoplasm in autophagic
vacuoles typically before cells undergo apoptosis. Finally,
mitotic catastrophe is described by prolonged mitotic
arrest with associated micro- and/or multinucleation prior
to undergoing death. Radiation-mediated cell death is
generally thought to occur primarily through either
apoptosis or mitotic catastrophe.
The notion that immunogenic-mediated cell death is also
an important aspect of RT response has been demonstrated
by several groups. Apetoh and colleagues immunized mice
with tumor cells previously exposed to either chemotherapy
or RT, and then re-challenged them with the tumor cells and
monitored for tumor growth [11]. Immunization with tumor
cells treated with either chemotherapy or RT prevented
regrowth of tumors in ~30% of mice as compared to mice
immunized with untreated tumor cells. When cells were
harvested from draining lymph nodes in immunized mice,
and rechallenged ex vivo, only lymph node cells from mice
immunized with tumor cells treated with RT produced
IFN-γ in response to re-challenge. Protective immunization in
this scenario was dependent on the presence of TLR-4 on
dendritic cells (DCs) and its ligand HMGB1, both released by
tumor cells following RT [11]. Two other factors, calreticulin
and ATP, also significantly contribute to immunogenic cell
death, in a manner similar to HMGB1, where cell death
triggers rapid translocation of calreticulin to the surface of
cells thereby promoting antigen presentation by dying cells
and DCs [79, 80]. Mice previously vaccinated with
irradiated tumor cells engineered to express an siRNA
against calreticulin exhibit a greatly reduced immune
response to challenge as compared to irradiated cells alone
[81].
Cytotoxic therapies (chemotherapy and RT) induce rapid
release of ATP from cells. ATP acts on the P2X(7)
purinergic receptor expressed by DCs, leading to activation
of the NOD-like receptor family, pyrin domain containing-3
protein (NLRP3)-dependent caspase-1 activation complex
(also known as the inflammasome). Inflammasome activa-
tion leads to release of pro-inflammatory cytokines such as
IL-1β, which are important for priming T cells. When
components of this pathway (NLRP3, caspase-1 or IL-1R)
are absent, reduced T cell responses towards cells killed by
chemotherapy or RT are observed [82], thus indicating that
release of ATP from dying cells is a critical aspect of
immunogenic cell death and anti-tumor immunity.
Further support for the importance of immunogenic cell
death mediated by HMGB1 and TLR-4 bearing DCs has
been provided by retrospective evaluation of a cohort of
breast cancer patients treated with adjuvant anthracyclines
following resection. Women harboring an Asp299Gly
TLR-4 polymorphism exhibited reduced response to
HMGB1, and a significantly higher rate of metastatic
disease [11]. Interestingly, similar to HMGB1, breast
cancer patients treated with anthracycline who harbored a
loss-of-function allele in P2RX7 (Glu496Ala) exhibited
significantly worse metastasis-free survival as compared to
patients with wildtype alleles [82].
RT and Activation of Innate Immune Programs Cells of the
innate and adaptive lineages work in concert to provide
rapid and effective responses to a wide variety of
pathogens. While cells of the innate lineage provide an
immediate and pre-programmed response, response by cells
of the adaptive lineage are delayed but instead are antigen-
specific and lead to prolonged memory [83]. Innate
leukocytes, including DCs, macrophages, natural killer
(NK) cells and mast cells, are referred to as “first
responders” to inflammatory mediators, largely based on
the fact that they are often prestationed in tissues.
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Naïve DCs continually sample antigens and migrate to
draining lymph nodes for antigen presentation to T cells
following their activation by “inflammatory mediators”. RT
induces opposing responses in tumors with regards to DCs:
directly-irradiated DCs are less effective APCs, however,
the tumor microenvironment generated by RT enhances
APC capabilities of DCs. In vitro examination of human
DCs has revealed that RT induced a “tolerogenic” phenotype
by decreasing the amount of IL-12 produced by mature DCs,
leading to decreased naïve CD8+ T cell priming [84].
However, when DCs are adoptively transferred into tumors
in combination with RT and chemotherapy in vivo, complete
regression of tumors is enhanced [85]. Thus, while
intratumoral DCs present at the time of chemotherapy or
RT yield reduced immune responsiveness, the environment
created by the RT fosters enhanced DC activation and
enhanced anti-tumor immunity.
Tumor-infiltrating macrophages, derived from circulating
monocytes, make up a substantial component of the leukocyte
infiltrate in solid tumors [86]. Macrophages exhibit either
anti- or pro- tumoral bioactivities dependent on the
cytokines, chemokines and soluble mediators they are
exposed to [87, 88]. Given this duality, it is not surprising
that the effect of radiation on macrophages is complex
with evidence that radiation can support either their anti-
or pro-tumor properties. Using human macrophage-
derived cell lines, Lambert and colleagues observed that
RT enhanced macrophage cytolytic activity [89]. Other
groups have reported that low dose whole-body RT
increased expression of TLR4/MD2 and CD14 expression
on murine peritoneal macrophages, leading to increased
secretion of anti-tumor cytokines including IL-12 and IL-18,
thus indicating that RT increases anti-tumor potential of
macrophages [90]. Despite the evidence that RT can
stimulate cytolytic activity and anti-tumor cytokine produc-
tion in macrophages, there also exists extensive literature
indicating that macrophages also promote resistance to RT.
In orthotopically-transplanted sarcoma and carcinomas,
presence of macrophages was inversely correlated with
tumor regression following RT [91]. In melanoma, local
RT of implanted tumors increased the number of APCs in
draining lymph nodes and increased the number of CD11b+
cells in tumors [71]. CD11b+ myeloid cells (a portion of
which are macrophages) contribute growth factors such as
vascular endothelial growth factor (VEGF) and matrix
metalloproteinase-9 (MMP-9) that supports angiogenic pro-
grams in growing tumors [92]. Preventing influx of CD11b+
myeloid cells following RT results in enhanced RT effects
[63, 93] likely due to their increased expression of T cell
suppressive molecules iNOS and arginase I [94, 95]. Thus,
while radiation can stimulate macrophage cytolytic activity
and anti-tumor cytokine production, this may be insufficient
to inhibit tumor growth if there is simultaneous recruitment
or activation of macrophages harboring dominant pro-tumor
properties.
NK cells are lymphoid cells that, unlike B and T cells, do
not possess specific antigen receptors, and thus are
considered innate lineage cells. NK cells play an important
role in tumors by targeting malignant cells by direct
cytolysis and secretion of potent immune mediators
including several cytokines and chemokines [96]. Exam-
ination of tumor cells exposed to ionizing radiation in vitro
indicates that RT induces expression of NKG2D ligands, an
activating receptor for NK cells [97, 98]. Other pro-
inflammatory stress molecules released by dying cells
include heat shock protein 70 (Hsp70), a stress response
protein with a role in binding defective proteins and
presenting them on the surface of cells [99]. When exposed
to RT, pancreatic and colon carcinoma cell release Hsp70,
thereby targeting them for lysis by NK cells [100]. That
NKG2D ligands and Hsp 70 render cells more susceptible to
NK-cell mediated cytolysis indicates that RT-stimulated NK
activity may be an important component of RT-induced
immune responsiveness.
Mast cells are pre-stationed in many tissues where they
act as important sentinel cells capable of mounting rapid
responses to tissue damage. Mast cells also accumulate in
tissues undergoing angiogenesis, wound healing and tissue
repair. During these processes, they secrete angiogenic
factors, such as vascular endothelial growth factor (VEGF),
and other inflammatory mediators such as histamine,
heparin cytokines, chemokines, proteases and lipid
mediators [101]. Heissig and colleagues reported that
low-dose irradiation fostered mast cell-dependent vascular
regeneration in a limb ischemia model where RT promoted
VEGF production by mast cells in a matrix metalloproteinase-
9 (MMP-9)-dependent manner [102]. RT, through MMP-9
up-regulated by VEGF in stromal and endothelial cells,
induced release of Kit-ligand (KitL) and promoted migration
of mast cells from bone marrow to the ischemic site [102]
similar to RT effects in the thoracic cavity where mast cell
density increased in bronchoalveolar lavage fluid [103].
Influx of mast cells following RT is blocked by treatment
with imatinib [104], a small molecule tyrosine kinase
inhibitor with activity against Kit, platelet derived growth
factor receptor (PDGFR) and Abelson Murine Leukemia
Viral Oncogene Homolog (Abl) [105]. Imatinib treatment
inhibited proliferation and induced apoptosis of mast cells
[106] and increased efficacy of RT in several murine tumor
models [107]. Given that low-dose RT fosters mast cell-
dependent vascular regeneration during limb ischemia
model, it seems reasonable to conclude that increased
recruitment and activation of mast cells following RT and
subsequent alterations in ischemic microenvironments and
activation of angiogenic programs may paradoxically foster
tumor growth.
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RT and Adaptive Immunity In experimental rodent models
of cancer development, e.g. brain, sarcoma, lung and
breast, RT alone or in combination with DC or
immunostimulatory therapies enhanced generation of
anti-tumor responses mediated by cytotoxic T cells [66,
72, 108]. RT alone can also stimulate anti-tumor T cell-
based immunity when given at high-doses by increasing
the number of activated CD8+ T cells [109–111]. In 4 T1
mammary tumors, recruitment of cytotoxic T cells is
dependent on CXCR6, a receptor for CXCL16. RT in
combination with anti-CTLA-4 mAB increases recruit-
ment of CXCR6+ CD8+ T cells [66]. Given that patients
undergoing RT for prostate cancer exhibited detectable
anti-tumor CD4+ and CD8+ T cells responses following
RT that were undetectable prior to therapy [112], it stands
to reason that in addition to genotoxic damage, induction
of anti-tumor immunity via T cell activation represents an
important mechanisms mediating the efficacy of RT-based
therapy.
Radiation and Immunotherapy
Preclinical Models Since one consequence of RT in tissues is
induction of various immune -mediated programs, several
groups have explored the potential of augmenting RT
responsiveness with immunotherapeutics (immunostimula-
tory cytokines, DC-based therapy and antibodies targeting T
cell costimulatory pathways) engineered to bolster anti-tumor
immunity.
Immunostimulatory cytokines including IL-2, IL-12
and TNF-α [54] have been used in combination with RT
to stimulate anti-tumor T cell responses. Addition of these
pro-inflammatory cytokines enhances RT efficacy by
bolstering cytotoxic T cell responses [113–117]. Interestingly,
IL-3, a cytokine that activates monocytes and mast cells
[118], delays tumor growth in response to RT [119]. The
enhanced tumor inhibition observed by combining cytokines
with RT provides evidence that effectiveness of RT depends
on immune-mediated mechanisms that can be targeted
effectively to enhance overall RT response. Based on this
postulate, several groups have attempted to increase the
presence of antigen-presenting DCs in tumors. Intratumoral
injection of CpG oligodeoxynucleotides that activate TLR9
on macrophages and DCs resulted in increased RT response
and resistance to a second challenge with the same tumor,
thus indicating development of a durable immune response
[120].
Antigen-presentation on the surface of DCs to T cells
requires both MHC and costimulatory molecules, B7
molecules and OX40 [121, 122]. Strategies to enhance
costimulatory molecules in combination with RT have been
employed in a transgenic model of colon carcinogenesis.
Carcinoma cells were engineered to express a human
antigen (CEA) – when RT was given in combination with
a viral vaccine expressing CEA and T cell co-stimulatory
molecules, complete tumor regression was observed ac-
companied by anti-tumor CD4+ and CD8+ T cell infiltration
[123]. Inhibition of tumor growth and enhanced overall
survival was also observed in a murine sarcoma model
when RT was given in combination with an agonistic
antibody for OX40, a costimulatory molecule found on
activated T cells that stimulates T cell proliferation and
differentiation [122]. Inhibition of CTLA-4 costimulation
also enhanced effectiveness of RT in 4 T1 mammary
carcinomas carcinoma resulting in diminished metastasis
and increased survival [124, 125]; however, RT dose and
timing were critical with regards to anti-CTLA-4 therapy
[126]. Despite these numerous successful preclinical trials
demonstrating efficacy of immune-modulation therapy in
combination with RT, only a few clinical studies have been
initiated to date.
Clinical Studies Clinical evaluation of RT in combination
with immunotherapeutic strategies are currently being
conducted for prostate, melanoma and liver carcinomas.
RT has been evaluated in conjunction with drugs that
inhibit androgen production resulting in enhanced auto-
antibody responses in 15–30% of prostate cancer patients
[127] and correlating with previous studies indicating that
anti-androgen therapy also increases T cell activity due to
thymic regrowth [128, 129]. Vaccination of prostate
cancer patients with recombinant viral-based vaccines
expressing prostate-specific antigen (PSA), in combina-
tion with the costimulatory molecule B7-1 and standard
RT to the prostate (70 Gy of RT in 1.8 to 2.0 Gy
fractions), resulted in a three-fold increase in PSA-
specific T cells and evidence of generating T cells
against other prostate-specific antigens in 76% of patients
[130]. Immunogenicity of irradiated tumor cells in
patients with melanoma was examined in which autolo-
gous irradiated melanoma cells engineered to express
GM-CSF, a white blood cell growth factor, were injected
into patients resulting in a significant anti-tumor immune
response leading to tumor regression in 50% of patients
[131]. The synergy between RT and DCs has been further
evaluated in a small study of patients with hepatoma
where DCs were injected intratumorally following a
single-dose of RT leading to development of tumor-
specific immune responses in 30% of patients [132].
Though these clinical studies involve small numbers of
non-randomized patients, they present compelling find-
ings indicating that the durability of RT may be enhanced
by combinatorial therapy with selective immune-based
therapeutics.
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Conclusions
Though many cancer patients will receive RT, it is clear that
clinician-scientists are only just beginning to understand the
full spectrum of biologic responses resultant from RT. RT
clearly influences multiple immune-based programs in
tissues, some of which lead to durable tumor regression,
whereas others propel tumor development. It seems
reasonable to conclude that identifying pathways mediating
activation of myeloid-based protumor immunity induced by
RT, will encourage development of novel therapeutics that
suppress those activities to effectively bolster RT responses.
Moreover, blockade of these protumor immune-based
pathways may also present the opportunity to then combine
RT with anti-tumor immunotherapeutics to yield effective
and durable suppression of tumors, resulting in improved
outcomes for patients with cancer.
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